AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts; Durable responses ...
Nasdaq

atai Life Sciences Reports Promising Phase 2a Results for BPL-003 in Alcohol Use Disorder with High Rates of Sustained Abstinence and Well-Defined Safety Profile

Atai Life Sciences announced positive results from a Phase 2a study of BPL-003, a synthetic intranasal treatment for alcohol use disorder (AUD), showing that a single dose combined with relapse ...
Nasdaq

atai Life Sciences Announces Positive Results from Phase 2a Study of BPL-003 for Treatment-Resistant Depression

Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...
Business Wire

First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression

BPL-003 is Beckley Psytech’s patent-protected benzoate formulation of 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device. The multi-centre, open ...